Ultromics Secures €48 Million In Series C Round

The round was co-led by L&G, Allegis Capital, and Lightrock, with continued backing from Oxford Science Enterprises, GV, Blue Venture Fund, and Oxford University. New investors include the University of Chicago Medicine and UPMC Enterprises.

“The reality is, hospitals already have the data, they just haven’t had the tools to extract diagnostic signals from it. By analysing routine echocardiograms with AI, we’re helping clinicians identify high-risk patients earlier, enabling intervention before disease progresses,” said Ross Upton, PhD, CEO and Founder, Ultromics. “We’ve spent years building our platform to fit into clinical workflows, with no extra hardware and no new friction, and this funding helps us scale that across the U.S. at a moment when health systems are actively looking to combat the growing heart failure crisis.”

Traditional methods often miss these diseases due to reliance on subjective readings of heart scans. As a result, up to 64% of HFpEF cases go undiagnosed, and cardiac amyloidosis is often mistaken for other issues—leading to delayed treatment.

Ultromics solves this with its AI-powered EchoGo platform, which analyzes standard heart scans to uncover hidden disease signals. It works with existing equipment and doesn’t disrupt clinical routines, helping doctors catch problems earlier and more accurately.

Read Also - Sava Secures $19M In Series A Round

With the new funding, Ultromics plans to grow across the U.S. and other major markets aiming to make AI diagnostics a standard part of heart exams. It will also expand its product range, explore new sales channels, and build more partnerships with hospitals and heart specialists.

So far, Ultromics has analyzed over 430,000 heart scans. Clinical trials show EchoGo improves HFpEF detection by 73.6% over standard methods. Their latest model for spotting cardiac amyloidosis also outperformed current tools in a global study involving 18 medical institutions.

“Ultromics has established itself as an early-mover in the large and underserved cardiovascular disease market, having developed one of the first commercially available AI-powered diagnostic echocardiogram technologies,” said Alastair Stewart, Head of Investments, Venture Capital, at L&G. “This successful Series C round is a testament to the massive opportunity for cutting-edge technology to transform how clinicians can detect and treat serious cardiovascular diseases that impact millions of people every year.”

Ultromics is rapidly gaining momentum through partnerships with top institutions like University of Chicago Medicine, University Hospitals Cleveland, Northwestern University, and Mayo Clinic. The company is forming strong regional hubs, especially in high-prevalence areas such as the U.S. Midwest.

Its AI platform helps hospitals cut down on unnecessary tests, improve workflow efficiency, and start treatment sooner—leading to better patient outcomes and lower healthcare costs.

“Heart failure and cardiac amyloidosis impact millions of lives and strain healthcare systems, despite new approaches that have the potential to significantly improve patient outcomes. There is a critical need for scalable solutions that enable earlier, mo re accurate diagnosis and elevate the standard of care,” said Umur Hursever, Partner at Lightrock. “Ultromics’ AI-driven technology is already making a real-world impact, improving diagnostic accuracy, supporting clinical decisions, and expanding access to specialist care. The Lightrock team is delighted to support Ultromics’ mission and growing impact.”

In late 2024, Ultromics secured FDA Breakthrough Device clearance for EchoGo Amyloidosis. Building on this milestone, the company launched EchoGo Score in 2025 a new feature that brings AI-powered probability scoring to EchoGo Heart Failure, giving clinicians deeper insights for detecting HFpEF more accurately.

“There’s a long-standing blind spot in cardiology where millions of patients with treatable heart failure are missed because their symptoms are subtle and echo images are hard to interpret,” said Victor Westerlind, Managing Director at Allegis Capital. “What’s exciting about Ultromics is how they’re closing that gap. Their platform brings AI and cardiology together in a way that makes it easier for physicians to identify high-risk patients earlier. When paired with the latest treatment advances, it’s a diagnostic win that will help save lives.”

About Ultromics

Founded in 2017, Ultromics has developed the first FDA-cleared and Medicare-reimbursed AI tool to help doctors detect two hard-to-diagnose heart conditions: HFpEF (Heart Failure with Preserved Ejection Fraction) and cardiac amyloidosis.